Estrella Immunopharma (ESLA) Return on Capital Employed (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Return on Capital Employed of 240.61% for Q1 2026, down 102371.0% year-over-year from N/an in Q1 2025, and up 87.74% quarter-over-quarter from 128.16% in Q4 2025.
Estrella Immunopharma (ESLA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Return on Capital Employed for 6 consecutive years, with 240.61% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 102371.0% year-over-year to 240.61%; the TTM figure through Mar 2026 stood at 240.61% (down 102371.0% YoY), while the FY2025 annual figure was 125.79%, up 123093.0% from the prior year.
- Return on Capital Employed climbed to 240.61% in Q1 2026 per ESLA's latest filing, from 128.16% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 1264.32% in Q1 2025 and bottomed at 3880.84% in Q4 2024.
- Historically, Return on Capital Employed has averaged 129.1% across 5 years, with a median of 1.79% in 2022.
- Annual changes were most pronounced in 2024 — Return on Capital Employed tumbled 381643 bps — and 2025, when it soared 400899 bps.
- Estrella Immunopharma's Return on Capital Employed stood at 34.2% in 2022, then slumped by 88 bps to 64.41% in 2023, then slumped by 5926 bps to 3880.84% in 2024, then surged by 103 bps to 128.16% in 2025, then surged by 88 bps to 240.61% in 2026.
- Business Quant data shows ESLA's Return on Capital Employed at 240.61% in Q1 2026, 128.16% in Q4 2025, and 166.96% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | 149.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 149.96% |
| Mar 31, 2026 | 240.61% |
| Dec 31, 2025 | 128.16% |
| Sep 30, 2025 | 166.96% |
| Jun 30, 2025 | 312.30% |
| Mar 31, 2025 | 1,264.32% |
| Dec 31, 2024 | -3,880.84% |
| Sep 30, 2024 | -1,239.35% |
| Jun 30, 2024 | -122.26% |
| Mar 31, 2024 | -41.33% |
| Dec 31, 2023 | -64.41% |
| Sep 30, 2023 | 775.24% |
| Jun 30, 2023 | 513.78% |
| Mar 31, 2023 | -203.04% |
| Dec 31, 2022 | -34.20% |
| Sep 30, 2022 | -8.02% |
| Jun 30, 2022 | -1.79% |
| Mar 31, 2022 | -0.86% |
| Dec 31, 2021 | -0.54% |